Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Nichols, Anthony C ^a   Black, Morgan ^a   Yoo, John ^a   Pinto, Nicole ^a   Fernandes, Andrew ^a   Haibe Kains, Benjamin ^b   Boutros, Paul C ^c,d,e   Barrett, John W ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell lines; Genomics; High throughput drug screening; HNSCC; Mutations

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; AZD 8055; BOSUTINIB; DOCETAXEL; GEFITINIB; METHOTREXATE; PF 562271; RAPAMYCIN; RETINOIC ACID; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; GENE DOSAGE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; NEXT GENERATION SEQUENCING; WART VIRUS; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL LINE; DRUG RESISTANCE; GENETICS; HEAD AND NECK NEOPLASMS; MUTATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT SCREENING ASSAYS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84924231068     PISSN: 20506511     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-66     Document Type: Article

References (36)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet 2008,371(9625):1695-1709. 10.1016/S0140-6736(08)60728-X
2. Baker SG, Sargent DJ: Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst 2010,102(23):1756-1759. 10.1093/jnci/djq427
3. Burtness B, Bauman JE, Galloway T: Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 2013,14(8):e302-309. 10.1016/S1470-2045(13)70085-8
4. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD: Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 2010,102(17):1310-1321. 10.1093/jnci/djq279
5. Hennessey PT, Ochs MF, Mydlarz WW, Hsueh W, Cope L, Yu W, Califano JA: Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One 2011,6(5):e20584. 10.1371/journal.pone.0020584
6. Lacroix M, Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004,83(3):249-289. 10.1023/B:BREA.0000014042.54925.cc
7. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN: Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011, 17:7248-7264. 10.1158/1078-0432.CCR-11-0690
8. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, et al.: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575. 10.1038/nature11005
9. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, et al.: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607. 10.1038/nature11003
10. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, et al.: The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160. 10.1126/science.1208130
11. Strimmer K: Fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 2008,24(12):1461-1462. 10.1093/bioinformatics/btn209
12. Strimmer K: A unified approach to false discovery rate estimation. BMC Bioinformatics 2008, 9:303. 10.1186/1471-2105-9-303
13. Efron B, Tibshirani R: Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol 2002,23(1):70-86. 10.1002/gepi.1124
14. Aubert J, Bar-Hen A, Daudin JJ, Robin S: Determination of the differentially expressed genes in microarray experiments using local FDR. BMC Bioinformatics 2004, 5:125. 10.1186/1471-2105-5-125
15. Rabinowits G, Haddad RI: Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012,48(11):1085-1089. 10.1016/j.oraloncology.2012.06.016
16. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, et al.: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157. 10.1126/science.1206923
17. Nichols AC, Palma DA, Chow W, Tan S, Rajakumar C, Rizzo G, Fung K, Kwan K, Wehrli B, Winquist E, Koropatnick J, Mymryk JS, Yoo J, Barrett JW: High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2013, 139:617-622. 10.1001/jamaoto.2013.3210
18. Brana I, Siu LL: Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012, 10:161. 10.1186/1741-7015-10-161
19. Gillet JP, Varma S, Gottesman MM: The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013,105(7):452-458. 10.1093/jnci/djt007
20. Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russell EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL, Ihde DC: Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Supplement 1996, 24:173-185.
21. Domcke S, Sinha R, Levine DA, Sander C, Schultz N: Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013, 4:2126.
22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314
23. Sharma SV, Haber DA, Settleman J: Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010,10(4):241-253. 10.1038/nrc2820
24. Nylander S, Kull B, Bjorkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skarby T, Inghardt T, Fjellstrom O, Gustafsson D: Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost 2012,10(10):2127-2136. 10.1111/j.1538-7836.2012.04898.x
25. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, et al.: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008,51(18):5522-5532. 10.1021/jm800295d
26. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR: Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer discovery 2013, 3:761-769. 10.1158/2159-8290.CD-13-0103
27. Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, Lee L, Lewis C, Nannini M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Wallin JJ, Wang L, Wei B, Sampath D, Olivero AG: Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1 ,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem 2013, 56:4597-4610. 10.1021/jm4003632
28. Rodon J, Juric D, Gonzalez-Angulo A, Bendell J, Berlin J, Bootle D, Gravelin K, Huang A, Derti A, Lehar J, Würthner J, Boehm M, van Allen E, Wagle N, Garraway LA, Yelensky R, Stephens PJ, Miller VA, Schlegel R, Quadt C, Baselga J: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. In American Association for Cancer Research. Washington, DC, USA;; 2013.
29. Juric D, Baselga J: Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol 2012,30(8):765-766. 10.1200/JCO.2011.39.6390
30. Juric D, Argiles G, Burris HA, Gonzalez-Angulo A, Saura C, Quadt C, Douglas M, Demanse D, De Buck S, Baselga J: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC). In Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium. vol. 72. San Antonio, TX: American Association of Cancer Research; 2012. Supplement 3
31. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422
32. Takeuchi K, Shin-ya T, Nishio K, Ito F: Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. Febs J 2009,276(5):1255-1265. 10.1111/j.1742-4658.2008.06861.x
33. van der Heijden MS, Bernards R: Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010,16(12):3094-3099. 10.1158/1078-0432.CCR-09-3004
34. Papillon-Cavanagh S, De Jay N, Hachem N, Olsen C, Bontempi G, Aerts HJ, Quackenbush J, Haibe-Kains B: Comparison and validation of genomic predictors for anticancer drug sensitivity. J Am Med Inform Assoc 2013,20(4):597-602. 10.1136/amiajnl-2012-001442
35. Tang AL, Hauff SJ, Owen JH, Graham MP, Czerwinski MJ, Park JJ, Walline H, Papagerakis S, Stoerker J, McHugh JB, Chepeha DB, Bradford CR, Carey TE, Prince ME: UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck 2012, 34:1480-1491. 10.1002/hed.21962
36. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE: Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010,32(4):417-426.